Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
This study is currently recruiting participants.
This is a Phase 1 clinical trial, a type of research study. The purpose of this phase 1 clinical trial is to find out whether a new study drug, ibrutinib, is safe in patients with T-cell non-Hodgkin lymphoma that has either come back or not responded to treatment. In this phase 1 study, different doses of ibrutinib (560 mg and 840 mg daily) will be tested to see what effect the drug has on the patient and the disease.
Study Type: Interventional
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter Phase I Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
Relapsed and Refractory T-cell Lymphoma
Interventions: Drug: Ibrutinib
Phase: Phase 1
External Link: https://clinicaltrials.gov/ct2/show/NCT02309580